Ghrelin administration suppresses inflammation‐associated colorectal carcinogenesis in mice

Ghrelin is a 28‐amino‐acid peptide that stimulates the release of pituitary growth hormone. Because of its orexigenic effects, ghrelin is being developed as a therapeutic option for postoperative support and treatment of anorexia‐cachexia syndrome of cancer patients. However, ghrelin has a multiplicity of physiological functions, and it also affects cell proliferation. Therefore, the effects of ghrelin administration on carcinogenesis and cancer progression in patients susceptible to cancer should be clarified. In this study, we examined the effects of ghrelin on cancer promotion in vivo using murine intestinal carcinogenesis models. Intestinal tumorigenesis was examined to determine the effects of either exogenous ghrelin administration or ghrelin deficiency following deletion of the Ghrl gene. Two murine intestinal tumorigenesis models were used. The first was the azoxymethane ( AOM )/dextran sodium sulfate ( DSS )‐induced inflammation‐associated colon carcinogenesis model and the second was the Apc Min/+ genetic cancer susceptibility model. In AOM / DSS ‐treated mice, administration of ghrelin significantly suppressed tumor formation in the colon. In contrast, ghrelin administration did not affect the number of intestinal tumors formed in Apc Min/+ mice. The absence of endogenous ghrelin did not affect the incidence of intestinal tumors in either AOM / DSS ‐treated mice or Apc Min/+ mice, though tumor size tended to be larger in Ghrl −/− colons in the AOM / DSS model. No tumor‐promoting effect was observed by ghrelin administration in either tumorigenesis model. In summary, this study provides in vivo experimental evidence for the usefulness of ghrelin administration in the chemoprevention of inflammation‐associated colorectal carcinogenesis and may suggest its safety in patients under colitis‐associated cancer susceptibility conditions.